Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02409342 · OUTCOME

Percentage of Participants With Anti-therapeutic Antibodies (ATAs)

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] · Source last updated 2023-03-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)

Analysis population: The baseline ADA-evaluable population included participants who had a baseline ADA result and had received at least one dose of atezolizumab. The post-baseline ADA evaluable population included participants who had at least one post-baseline ADA result and had received at least one dose of atezolizumab.

Groups in this outcome

Atezolizumab

Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab282

Reported measurements

Baseline evaluable participants

Analysis denominator · Participants

GroupSource count
Atezolizumab282
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab1.4Not reportedNot reportedNot reportedNot reported
Post-baseline evaluable participants

Analysis denominator · Participants

GroupSource count
Atezolizumab267
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab24.3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1.4
    denoms
    1. counts
      1. group Id
        OG000
        value
        282
      units
      Participants
    title
    Baseline evaluable participants
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        24.3
    denoms
    1. counts
      1. group Id
        OG000
        value
        267
      units
      Participants
    title
    Post-baseline evaluable participants
denoms
  1. counts
    1. group Id
      OG000
      value
      282
    units
    Participants
groups
  1. description
    Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
    id
    OG000
    title
    Atezolizumab
param Type
NUMBER
population Description
The baseline ADA-evaluable population included participants who had a baseline ADA result and had received at least one dose of atezolizumab. The post-baseline ADA evaluable population included participants who had at least one post-baseline ADA result and had received at least one dose of atezolizumab.
reporting Status
POSTED
time Frame
Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)
title
Percentage of Participants With Anti-therapeutic Antibodies (ATAs)
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice